Introducing Biosimilars into Current Inflammatory Bowel Disease Treatment Algorithms

Disclosure: Prof Simon Travis has been an advisor to, in receipt of educational or research grants from, or an invited lecturer for AbbVie, Amgen, Asahi, Biogen, Boehringer Ingelheim, BMS, Cosmo, Elan, Ferring, FPRT Bio, Genentech/Roche, Genzyme, Glenmark, GW Pharmaceuticals, Lilly, Merck, Novartis, Novo Nordisk, Ocera, Pfizer, Receptos, Shire, Santarus, SigmoidPharma, Synthon, Takeda, Tillotts, Topivert, Trino Therapeutics with Wellcome Trust, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott, and Zeria. All advisory boards were suspended 2012–14 whilst President of ECCO. Prof Geert R D’Haens has served as an advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, BMS, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, DrFALK Pharma, Engene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp & Dohme, Mundipharma, Novonordisk, Pfizer, Prometheus laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor, and has received speaker fees from AbbVie, Ferring, Johnson and Johnson, Merck Sharp & Dohme, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts, and Vifor. Dr Julián Panés has been advisor to, in receipt of educational or research grants from, or an invited lecturer for AbbVie, Biogen, Boehringer Ingelheim, Celgene, Ferring, Galapagos, Genentech/Roche, GSK, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Takeda, TiGenix, and Topivert. Prof Stefan Schreiber has received honoraria from Biogen. Acknowledgements: Writing assistance provided by Juliette Allport, Ashfield Healthcare Communications Ltd. Support: Biogen provided funding for medical writing support in the development of this article. Biogen reviewed the article for medical accuracy and provided feedback to the authors. All named authors had full editorial control of the paper, and provided their final approval of all the content. Citation: EMJ Gastroenterol. 2016;5[1]:34-41.